CHEK2 and cancer: All BC c.1009-118_1009-87delinsC variant carriers with known histology (18/21) developed ER-positive primary tumors, six developed double-primary cancers, and only two with known family cancer history (18/21) had negative or CHEK2-irrelevant family cancer history (Table 1).